Stanolone

Stanolone

SCHEMBL333299

C[C@]12CCC(=O)CC1CC[C@@H]1[C@H]2CC[C@]2(C)C(O)CC[C@@H]12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SHBG P04278 6/20 1.00
GPBAR1 Q8TDU6 4/20 1.00
CYP19A1 P11511 2/20 1.00
NR3C1 P04150 1/20 1.00
PGR P06401 1/20 1.00
SERPINA6 P08185 1/20 1.00
NR3C2 P08235 1/20 1.00
CYP3A4 P08684 1/20 1.00
AR P10275 1/20 1.00
HSD17B10 Q99714 1/20 1.00
MGAM O43451 1/20 1.00
AKR1B10 O60218 3/20 0.70
AKR1B1 P15121 3/20 0.70
PDK1 Q15118 2/20 0.68
PDK2 Q15119 2/20 0.68
PDK3 Q15120 2/20 0.68
PDK4 Q16654 2/20 0.68
POLB P06746 1/20 0.66
MAPK1 P28482 1/20 0.66
OR51E2 Q9H255 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Stanolone SCHEMBL619535 1.00 SHBG (1.00) SHBGGPBAR1CYP19A1NR3C1PGR
Stanolone SCHEMBL3486722 1.00 SHBG (1.00) SHBGGPBAR1CYP19A1NR3C1PGR
Stanolone SCHEMBL1502216 1.00 SHBG (1.00) SHBGGPBAR1CYP19A1NR3C1PGR
Stanolone SCHEMBL15963544 1.00 SHBG (1.00) SHBGGPBAR1CYP19A1NR3C1PGR
Stanolone SCHEMBL24684703 1.00 SHBG (1.00) SHBGGPBAR1CYP19A1NR3C1PGR
Stanolone SCHEMBL1570704 1.00 SHBG (1.00) SHBGGPBAR1CYP19A1NR3C1PGR
Stanolone SCHEMBL24410503 1.00 SHBG (1.00) SHBGGPBAR1CYP19A1NR3C1PGR
Stanolone SCHEMBL9340073 1.00 SHBG (1.00) SHBGGPBAR1CYP19A1NR3C1PGR
Stanolone SCHEMBL21442439 1.00 SHBG (1.00) SHBGGPBAR1CYP19A1NR3C1PGR
Stanolone SCHEMBL27379 1.00 SHBG (1.00) SHBGGPBAR1CYP19A1NR3C1PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 344 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12029741-B1 5 beta dihydrotestosterone pharmaceutical formulations and related methods CORBOY JR EDWARD DUNNE (US) 2024-07-09 US claimed
US-20220057384-A1 SLEEP MODULATION AGENT OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2022-02-24 US claimed
US-20100317639-A1 Medicament Based On a Monoester of Steroids With Long Chain Fatty Acids PETRONI ANNA 2010-12-16 US claimed
EP-1962856-B1 MEDICAMENT BASED ON A MONOESTER OF STEROIDS WITH LONG CHAIN FATTY ACIDS PETRONI ANNA (IT) 2010-10-20 EP claimed
EP-1807062-A4 USE OF ANDROGENS TO REDUCE THE LIKELIHOOD OF ACQUIRING OR TO TREAT SKIN AGING ENDORECH INC (CA) 2009-06-03 EP claimed
EP-1807062-A1 USE OF ANDROGENS TO REDUCE THE LIKELIHOOD OF ACQUIRING OR TO TREAT SKIN AGING Endorecherche Inc. (CA) 2007-07-18 EP claimed
US-20060178352-A1 Use of androgens to reduce the likelihood of acquiring or to treat skin aging ENDORECHERCHE, INC. 2006-08-10 US claimed
WO-2006047859-A1 USE OF ANDROGENS TO REDUCE THE LIKELIHOOD OF ACQUIRING OR TO TREAT SKIN AGING ENDORECHERCHE, INC. (CA) 2006-05-11 WO claimed
US-20040223983-A1 Pharmaceutical preparations, use of these preparations and process for increasing the biovailability of pharmaceutical substances to be administered perorally BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-11-11 US claimed
EP-0700291-A4 15-SUBSTITUTED 4-AZASTEROIDS MERCK & CO INC (US) 1996-07-03 EP claimed
EP-0700291-A1 15-SUBSTITUTED 4-AZASTEROIDS MERCK & CO. INC. (US) 1996-03-13 EP claimed
US-5439900-A Synergistic mixture of steroid and alcohol BUKUSOGLU CUNEYT (US) 1995-08-08 US claimed
US-4097334-A Process for the preparation of androstane-3,17-dione derivatives SCHERING AKTIENGESELLSCHAFT (DT) 1978-06-27 US claimed
US-12029741-B1 5 beta dihydrotestosterone pharmaceutical formulations and related methods CORBOY JR EDWARD DUNNE (US) 2024-07-09 US disclosed
US-12029741-B1 5 beta dihydrotestosterone pharmaceutical formulations and related methods CORBOY JR EDWARD DUNNE (US) 2024-07-09 US disclosed
US-20240117436-A1 METHODS OF TREATING LIPEDEMA INCLUDING AKR1C2 AS A THERAPEUTIC TARGET MAGI EUREGIO SCS (IT) 2024-04-11 US disclosed
US-4097334-A Process for the preparation of androstane-3,17-dione derivatives SCHERING AKTIENGESELLSCHAFT (DT) 1978-06-27 US disclosed
US-4092413-A Antiandrogens as platelet aggregation inhibitors MERCK & CO., INC. (US) 1978-05-30 US disclosed
US-4013688-A STEROIDS THE UPJOHN COMPANY (US) 1977-03-22 US disclosed
US-3990956-A Electrochemical reduction of α,β-unsaturated keto steroids SCHERING AKTIENGESELLSCHAFT (DT) 1976-11-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317639-A1 Medicament Based On a Monoester of Steroids With Long Chain Fatty Acids ACAT1, ACAT2, HSD17B12 SHBG 328/4885GPBAR1 360/4885CYP19A1 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.